AGENDA:
Proposed New Rules and Amendments Related to Vendor Drug Program Reimbursement,
Prescription of Drugs During Disasters, Audit Appeals, and the Drug Utilization Review Board
November 23, 2015
10 a.m. to 11 a.m.
Meeting Site:
Health and Human Services Commission
Brown-Heatly Building
Public Hearing Room
4900 North Lamar Blvd.
Austin, Texas 78751
Health and Human Services Commission (HHSC) will conduct a public hearing to receive comments on proposed new rules and amendments to different sections within Title 1, Part 15, Chapters 353 and 354 of the Texas Administrative Code:
- For rules related to Medicaid fee-for-service and prescription drugs during a disaster: Chapter 354, Subchapter F, §354.1835, Prescriber Identification Numbers; §354.1851, Substitution of One Drug for Another in a Prescription; §354.1863, Prescription Requirements; §354.1901, Pharmacy Claims; §354.1921, Addition of Drugs to the Texas Drug Code Index; §354.1923, Review and Evaluation; and §354.1927, Retention and Deletion of Drugs. HHSC also proposes new Title 1, Part 15, Chapter 354, Subchapter F, Division 4, §354.1868, Exceptions in Disasters. See 40 Tex. Reg. 7505.
- For rules related to audit appeals: Chapter 354, Subchapter F, Division 5, §354.1891, concerning Vendor Drug Providers Subject to Audit. See 40 Tex. Reg. 7754
- For rules related to the Drug Utilization Review Board: Chapter 354, Subchapter F, §354.1832, concerning Prior Authorization Procedures; and §354.1924, concerning Preferred Drug List. HHSC proposes to repeal §354.1928, concerning Pharmaceutical and Therapeutics Committee, and §354.1941, concerning Conflict of Interest Policy. HHSC proposes as new §354.1941, concerning Drug Utilization Review Board; and §354.1942, concerning Conflict of Interest Policy. See 40 Tex. Reg. 7750
- For rules related to clinical prior authorization and the Drug Utilization Review Board: Chapter 353, Subchapter J, §353.903, concerning Definitions; and §353.907, concerning Prior Authorization Requirements. See 40 Tex. Reg. 7749
The aforementioned proposals are too lengthy and complex to discuss in this public hearing notice. Yet, the proposals were published in two separate issues of the Texas Register and the reader can explore in detail each proposal in said publications. For the reader’s convenience, the Texas Register publications associated with each proposed new rule and amendment are hyperlinked in the above-listed citations.
Written Comments. Written comments on the proposed new rule and amendments may be submitted at the public hearing or to Stacey Johnston at: Vendor Drug Program, Mail Code 2250, P.O. Box 85200, Austin, Texas 78708-5200; by fax at 512-730-7483; or by email to Stacey.Johnston@hhsc.state.tx.us within 30 days of publication of this proposal in the Texas Register.
People requiring Americans with Disabilities Act accommodation, auxiliary aids or services should contact Kristine Dahlmann at 512-462-6299 at least 72 hours before the hearing so appropriate arrangements can be made.